LADX

LadRx Corporation

LADX, USA

LadRx Corporation, a biopharmaceutical company, engages in research and development of chemotherapeutic drugs for solid tumors in the United States. The company offers linker activated drug releases (LADR) technology, a platform consists of an organic backbone that is attached to a chemotoxic agent that targets and delivers the chemotoxic agent to the tumor environment and release within the tumor. Its lead candidates comprising LADRs 7, 8, 9, and 10 with novel derivatives of the auristatin and maytansinoid drug targeting tumors; and aldoxorubicin, which is in phase II clinical development for the treatment of pancreatic cancer. In addition, the company develops albumin companion diagnostic (ACDx) to identify patients with cancer that benefits from treatment with the four LADR lead candidates. The company was formerly known as CytRx Corporation and changed its name to LadRx Corporation in September 2022. The company was incorporated in 1985 and is headquartered in Los Angeles, California.

https://www.ladrxcorp.com

Stock Price

$0.00

0%

decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
LADX
stock
LADX

LadRx Liquidates Assets Amid Leadership Resignations TipRanks

Read more →

Finn Analysis

(Last Updated 2025-03-31)

Health Score

Price to Book Ratio (P/B)

-

Very Low

-0.00

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very High

33.69 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-276.57 %

Low ≤ 2%

High ≥ 10%

Investors

* Institutions hold a combined 0.00% of the total shares of LadRx Corporation

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

—

EPS Estimate

—

Latest Release

Date

2025-03-31

EPS Actual

-1.4528

EPS Estimate

—

EPS Difference

0

Surprise Percent

0%

Investing Fit Scorecard

(Last Updated 2025-03-31)

Deep Value
Weak Deep Value(2)
Defensive
Moderately Defensive(5.5)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(5.3)
GARP
Not Attractive for GARP(2)
Growth
Weak Growth Prospect(2.5)
Momentum
No Momentum(2)
Net Net
Not Undervalued (Net-Net)(2)
Quality
Low Quality Business(2.5)
Value
Overpriced(2.5)

Income Statement

(Last Updated 2025-03-31)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-03-31)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-03-31)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.